These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21576452)

  • 21. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
    Walmsley SL; Katlama C; Lazzarin A; Arestéh K; Pierone G; Blick G; Johnson M; Meier U; MacGregor TR; Leith JG
    J Acquir Immune Defic Syndr; 2008 Apr; 47(4):429-40. PubMed ID: 18176328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
    Mathias AA; Hinkle J; Shen G; Enejosa J; Piliero PJ; Sekar V; Mack R; Tomaka F; Kearney BP
    J Acquir Immune Defic Syndr; 2008 Oct; 49(2):156-62. PubMed ID: 18769354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
    King JR; Khatri A; Trinh R; Viani RM; Ding B; Zha J; Menon R
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
    Hill A; Moyle G
    HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
    De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
    Ter Heine R; Mulder JW; van Gorp EC; Wagenaar JF; Beijnen JH; Huitema AD
    Br J Clin Pharmacol; 2010 May; 69(5):475-83. PubMed ID: 20573083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.
    Goebel FD; MacGregor TR; Sabo JP; Castles M; Johnson PA; Legg D; McCallister S
    HIV Clin Trials; 2010; 11(1):28-38. PubMed ID: 20400409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
    Cattaneo D; Gervasoni C; Cozzi V; Baldelli S; Fucile S; Meraviglia P; Landonio S; Boreggio G; Rizzardini G; Clementi E
    Pharmacol Res; 2012 Feb; 65(2):198-203. PubMed ID: 21958880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
    Ruxrungtham K; Boyd M; Bellibas SE; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH
    J Clin Pharmacol; 2004 Jul; 44(7):793-803. PubMed ID: 15199084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients.
    Morello J; De Mendoza C; Soriano V; Anta L; González-Pardo G; Corral A; Blanco F; Jiménez-Nácher I; González-Lahoz J; Rodríguez-Novoa S
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4153-8. PubMed ID: 19596874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
    Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
    Youle M; Staszweski S; Clotet B; Arribas JR; Blaxhult A; Carosi G; Dejesus E; Di Perri G; Estrada V; Fisher M; Kovacs C; Kulasegaram R; Lazzarin A; Marriott D; Muñoz L; Reynes J; Shalit P; Slim J; Tsoukas C; Vaccaro A; Vera J
    HIV Clin Trials; 2006; 7(2):86-96. PubMed ID: 16798623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
    Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New therapeutic options in protracted HIV-infected patients with virological failure].
    Moreno Cuerda VJ; Rubio García R; Morales Conejo M
    Med Clin (Barc); 2008 Jan; 130(2):66-70. PubMed ID: 18221677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir.
    Pierone G; Urban T; Martin A; Mieras J; Kantor C
    HIV Clin Trials; 2008; 9(2):140-1. PubMed ID: 18474499
    [No Abstract]   [Full Text] [Related]  

  • 37. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
    Arribas JR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When and how to use tipranavir and darunavir.
    Hoffman CJ; Gallant JE
    AIDS Read; 2007 Apr; 17(4):194-8, 201. PubMed ID: 17479503
    [No Abstract]   [Full Text] [Related]  

  • 40. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
    Temesgen Z; Feinberg J
    Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.